Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth

Not Applicable

Completed

• Conditions: Asymptomatic Bacteriuria in Pregnancy; Preterm Birth
• Interventions: Combination Product: Griess,

• Registration Number: NCT03274960
• Lead Sponsor: University of Zimbabwe

Brief Summary

This study is evaluating whether screening of a pregnant woman for asymptomatic bacteriuria in each trimester for early detection and treatment of bacteriuria will reduce the incidence of preterm birth in Harare.

Detailed Description

Asymptomatic bacteriuria is common in pregnancy. If the disease is not detected early in pregnancy and treated it often progresses to an acute symptomatic disease, pyelonephritis which is associated with adverse pregnancy outcomes including preterm birth.

It is recommended that every woman be screened for asymptomatic bacteriuria by urine culture test at initial antenatal care visit so that the disease is if identified is treated early to prevent preventable complications of the disease in pregnancy. Culture test is expensive and therefore unavailable at several primary care settings especially in low resource settings where majority of pregnant women register and visit for antenatal care. In Zimbabwe antenatal care at primary care clinics is not including screening for asymptomatic bacteriuria. Majority who present with symptoms are empirically treated.

In this study the Griess nitrite test, an effective inexpensive screening test for asymptomatic bacteriuria is used. the test detects nitrite in urine which is associated with presence of nitrate reducing uropathogens, commonly the gram negative bacteria. All the positive samples will then be further tested by culture for bacteria identification, quantification and antibiotic sensitivity. A Randomized controlled trial research design is being used. participants are randomly allocated to intervention group or control group. Urine samples will be collected and tested 3 times for each recruited participant in the intervention arm. treatment will be initiated for positive result according to sensitivity test. Control group will only be subjected to routine existing antenatal care.

Participants will be recruited before 22 weeks gestation and followed on for second contact by 28 weeks and third contact by 36 weeks. Follow up will be stopped on delivery for noting gestation at delivery, whether preterm or term.

Study Timeline

• Study Start: 2017-02-23
• Study First Submitted: 2017-08-25
• Study First Submitted QC: 2017-09-04
• Study First Posted: 2017-09-07
• Primary Completion: 2020-01-30
• Study Completion: 2020-12-30
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-09
• Last Update Posted: 2023-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 480

Inclusion Criteria

• Pregnant women registering at study site.
• Woman is able to identify her date of last menstrual period.
• Gestation of pregnancy is between 6 and 22 weeks.
• Woman is asymptomatic for bacteriuria
• Woman voluntarily signs the consent form

Exclusion Criteria

• Pregnant woman ill and unwell
• Pregnant woman unwilling to sign consent form
• Woman who had antibiotic treatment 2 weeks before recruitment
• Woman on long term antibiotic treatment
• Woman who fails to identify date of last menstrual period
• Woman symptomatic for urinary tract infection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Griess, Culture and antibiotic	Griess,	Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.

Primary Outcome Measures

Name	Time	Method
Preterm birth	Preterm birth will be calculated as gestation at birth of baby using date of birth and the first date of last menstrual period.	Preterm birth will be delivery of a baby before 37 complete weeks of gestation from the first date of last menstrual period. It will be sub-categorized as extremely preterm (\<28 weeks), very preterm (28 to \<32 weeks) and moderate to late preterm (32 to \<37 weeks).

Secondary Outcome Measures

Name	Time	Method
Antibiotic sensitivity	These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening	from urine culture results identified antibiotics sensitive for treatment of isolated bacteria will be noted.
Isolated uropathogen	These will be available at recruitment by 22 weeks, between 22 and 28 weeks at second screening and at 28 to 36 weeks at the third screening.	All isolated bacterial species from urine sample identified from culture test. These are bacteria identified to be responsible for asymptomatic bacteriuria.
symptomatic bacteriuria	The symptoms will be noted at interviews at follow up after every 6 to 8 weeks from previous contact.	Noted from history of urinary tract symptoms which include pain on micturition, fever, blood in urine, increased urine frequency, foul smelling urine and cloudy urine.
Gestation at birth	Gestation will be calculated at delivery of baby.	Gestation is the calculated total number of weeks from first date of last menstrual period to the date of delivery.

Trial Locations

Locations (1)

University of Zimbabwe; 🇿🇼 Harare, Metropolitan, Zimbabwe